SCHEMBL6765302

SCHEMBL6765302

CC(C)(O)CC(=O)Nc1cc(Cl)ccc1OCC(=O)N1[C@@H]2CC[C@H]1CC(Oc1ccc(F)cc1)C2

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 7/20 0.43
FPR3 P25089 1/20 0.43
GPR65 Q8IYL9 1/20 0.43
GPR35 Q9HC97 1/20 0.43
TSHR P16473 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
HTT P42858 1/20 0.38
EPHX2 P34913 1/20 0.38
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
USP2 O75604 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
MAPT P10636 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CASP6 P55212 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6765304 1.00 CCR1 (0.43) CCR1FPR3GPR65GPR35TSHR
SCHEMBL6762090 0.87 CCR1 (0.54) CCR1FPR3GPR65GPR35TSHR
SCHEMBL6155895 0.87 CCR1 (0.54) CCR1FPR3GPR65GPR35TSHR
SCHEMBL6155902 0.87 CCR1 (0.54) CCR1FPR3GPR65GPR35TSHR
SCHEMBL6762106 0.84 TSHR (0.42) CCR1FPR3GPR65GPR35TSHR
SCHEMBL6762108 0.84 TSHR (0.42) CCR1FPR3GPR65GPR35TSHR
SCHEMBL6761289 0.83 CCR1 (0.41) CCR1FPR3GPR65GPR35TSHR
SCHEMBL6761287 0.83 CCR1 (0.41) CCR1FPR3GPR65GPR35TSHR
SCHEMBL6758352 0.81 TSHR (0.43) CCR1TSHRHTTEPHX2KMT2A
SCHEMBL6758359 0.81 TSHR (0.43) CCR1TSHRHTTEPHX2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063688-A1 Novel piperidine derivatives PFIZER INC. 2004-04-01 US claimed
US-20040063688-A1 Novel piperidine derivatives PFIZER INC. 2004-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063688-A1 Novel piperidine derivatives CCR1, CCR3, CCR2 CCR1 1/4885FPR3 43/4885GPR65 214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.